First Episealer® surgery in the Asia-Pacific
Episurf Medical (Nasdaq: EPIS B) today announces that the first surgery with the knee implant Episealer® in the Asia-Pacific region has been scheduled.
“This is a significant milestone for us, and we have identified significant opportunities in the Asia-Pacific region. Recently, we have increased our focus towards several new markets, in which the regulatory work is ongoing. Scheduling the first surgery outside of Europe is exciting. We are also happy for the fact that we are reaching commercial milestones, simultaneously as we are making significant progress within the clinical strategy” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.